Last €83.58 EUR
Change Today +2.41 / 2.97%
Volume 5.5M
As of 11:37 AM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

sanofi (SAN) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/30/14 - €89.95
52 Week Low
02/6/14 - €68.29
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SANOFI (SAN)

sanofi (SAN) Details

Sanofi discovers, develops, and distributes therapeutic solutions. Its primary products include Lantus and Apidra analogs of human insulin; Insuman insulin solutions and suspensions; Amaryl, a sulfonylurea; Lyxumia, a prandial GLP-1 receptor agonist; BGStar, iBGStar, and MyStar Extra blood glucose meters; Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme for mucopolysaccharidosis Type I; Aubagio for multiple sclerosis; and Lemtrada, a humanized monoclonal antibody. The company’s products also comprise Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; Jevtana for prostate cancer; Thymoglobulin, an immuno-suppressive and immuno-modulating agent; Mozobil stem cell mobilizer; and Zaltrap recombinant fusion protein. In addition, it offers thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. Further, it provides Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements for pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has a strategic alliance with Illumina, Inc. to develop a next-generation sequencing based oncology test system. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

112,128 Employees
Last Reported Date: 03/7/14
Founded in 1973

sanofi (SAN) Top Compensated Officers

Chairman, Interim Chief Executive Officer, Ch...
Total Annual Compensation: €700.0K
Compensation as of Fiscal Year 2013.

sanofi (SAN) Key Developments

VECT-HORUS Announces Signing of Scientific Collaboration Agreement with Sanofi

VECT-HORUS announced the signing of a scientific collaboration agreement with SANOFI. The goal of this collaboration is to use VECT-HORUS' proprietary technology to transport therapeutic antibodies into the brain for the treatment of a neurodegenerative disease. The blood-brain barrier (BBB) restricts very effectively the passage of imaging or therapeutic agents from blood to brain. Effectiveness of this barrier increases with the size of the molecules and as a consequence, the vast majority of the innovative biomolecules developed by the pharmaceutical industry, including peptides, proteins, therapeutic antibodies, with promising potential in the field of brain disorders, do not cross the BBB. CNS diseases represent a high unmet medical need and already the second large therapeutic market, in spite of the fact that there is still no cure or efficient treatments to tackle neurodegenerative diseases. Transporting drugs across the BBB is thus a technological barrier that VECT-HORUS intends to lift, allowing thereby the treatment of neurodegenerative diseases, particularly with therapeutic antibodies. The scientific approach of the company is based on the principle that the BBB is not only a physical barrier that must be crossed, but also a functional barrier whose natural transport mechanisms may be advantageously used to deliver drugs into the brain. The peptide-vectors developed by VECT-HORUS use endogenous transport mechanisms to facilitate the passage of drugs or imaging agents across the BBB, into the pathological brain.

Sanofi, Boehringer Ingelheim Enter into Monoclonal Antibodies Partnership

Sanofi announced that it has sealed a strategic partnership with Boehringer Ingelheim to produce therapeutic monoclonal antibodies. The partnership is aimed at boosting Sanofi's manufacturing capacity and supporting upcoming product launches. Under the terms of the agreement, Boehringer Ingelheim will grant Sanofi access to its Biberach an der Riss capacity in Germany to allow the French company to transfer production of its monoclonal antibodies (mAbs). The product transfer will be initiated in shortest terms this year.

Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Sanofi

Glancy Binkow & Goldberg LLP announced that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of a class comprising purchasers of the securities of Sanofi between February 7, 2013 and December 3, 2014, inclusive. The complaint alleges that defendants misrepresented or failed to disclose that the company was making improper payments to healthcare professionals in connection with the sale of pharmaceutical products, in violation of federal law, and that Sanofiâ s internal controls over financial reporting were inadequate. On October 6, 2014, Sanofi issued a statement announcing that the company was investigating allegations related to improper payments to healthcare workers in connection with the sale of pharmaceutical products that may have occurred between 2007 and 2012 in certain parts of the Middle East and East Africa. Then, on October 29, 2014, Sanofi announced that its Board of Directors had decided to terminate Christopher A. Viehbacher from his position as Chief Executive Officer of Sanofi. On December 3, 2014, media outlets reported that a former Sanofi employee filed a whistleblower lawsuit in New Jersey against the company, alleging that the recently ousted CEO and other executives at the company participated in a scheme â over the course of many years to funnel tens of millions of dollars in kickbacks and other incentives to get the company's diabetes drugs prescribed and sold.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAN:FP €83.58 EUR +2.41

SAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $62.43 USD -0.55
Amgen Inc $159.81 USD +0.24
Bayer AG €128.07 EUR +4.14
Bristol-Myers Squibb Co $62.07 USD -0.02
GlaxoSmithKline PLC 1,500 GBp +11.50
View Industry Companies

Industry Analysis


Industry Average

Valuation SAN Industry Range
Price/Earnings 24.0x
Price/Sales 2.9x
Price/Book 1.9x
Price/Cash Flow 14.8x
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at